Tina Foster
Family · Owensboro, KYNPI 1942972146
Payments from drug & device makers
Across 255 payments — averaging $15.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$1K
- Alkermes, Inc.$572
- Teva Pharmaceuticals USA, Inc.$451
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$349
- Vanda Pharmaceuticals Inc.$336
- Indivior Inc.$200
- plus $1K from 15 others
What the payments were for
- Food & beverage$4,059100%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 74 | $1,001 |
| Alkermes, Inc. | 32 | $572 |
| Teva Pharmaceuticals USA, Inc. | 29 | $451 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 22 | $349 |
| Vanda Pharmaceuticals Inc. | 19 | $336 |
| Indivior Inc. | 11 | $200 |
| Neurocrine Biosciences, Inc. | 12 | $199 |
| Otsuka America Pharmaceutical, Inc. | 9 | $155 |
| Axsome Therapeutics, Inc. | 8 | $142 |
| Lundbeck LLC | 8 | $136 |
| AbbVie | 6 | $106 |
| Braeburn Inc. | 4 | $84 |
| E.r. Squibb & Sons, L.L.C. | 4 | $72 |
| Noven Therapeutics, LLC | 4 | $64 |
| Ironshore Pharmaceuticals Inc. | 3 | $57 |
| Corium, LLC | 3 | $47 |
| Avanir Pharmaceuticals, Inc. | 2 | $30 |
| GSK | 2 | $30 |
| Biogen | 1 | $16 |
| Tris Pharma Inc | 1 | $13 |
| Almatica Pharma LLC | 1 | $12 |
How this compares
$4,071 in reported general payments places this provider in the 85th percentile of 4,374 family providers in Kentucky.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 21 | $13,973 |
| Celecoxib | 15 | $1,010 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 18 | $678 |
| Fluticasone Propionate | 21 | $229 |
| Levothyroxine Sodium | 24 | $213 |
| Atorvastatin Calcium | 42 | $151 |
| Lisinopril | 36 | $126 |
| Pantoprazole Sodium | 11 | $72 |
| Metformin Hcl | 23 | $66 |
| Omeprazole | 19 | $62 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta | $30 | $13,97321 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,374 family providers in Kentucky.
Other family in Owensboro
- Jason SandersOwensboro$30K
- Melanie McCartyOwensboro$15K
- Bonnie HillLouisa$372K
- Ashley SnellenElizabethtown$190K
- Smita RanjanLouisville$92K
- Elizabeth SaltLexington$89K
- Tracey GaslinLouisville$79K
- Kassandra GreenLouisville$69K
- Danielle RevertLouisville$65K
- Lora BrownMonticellow$61K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.